Robbie Marcus
Stock Analyst at JP Morgan
(3.59)
# 932
Out of 4,667 analysts
146
Total ratings
66.67%
Success rate
14.24%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CBLL CeriBell | Initiates: Overweight | $32 | $25.06 | +27.69% | 1 | Nov 5, 2024 | |
| SYK Stryker | Maintains: Overweight | $375 → $420 | $385.68 | +8.90% | 8 | Oct 30, 2024 | |
| ATRC AtriCure | Maintains: Overweight | $30 → $40 | $36.03 | +11.02% | 5 | Oct 30, 2024 | |
| EW Edwards Lifesciences | Maintains: Neutral | $72 → $78 | $69.54 | +12.17% | 4 | Oct 25, 2024 | |
| DXCM DexCom | Maintains: Neutral | $75 → $85 | $75.24 | +12.97% | 2 | Oct 25, 2024 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $495 → $575 | $541.82 | +6.12% | 4 | Oct 11, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Neutral | $125 → $120 | $109.27 | +9.82% | 4 | Sep 16, 2024 | |
| GEHC GE HealthCare Technologies | Initiates: Neutral | $90 | $84.90 | +6.01% | 1 | Sep 9, 2024 | |
| ENOV Enovis | Maintains: Neutral | $53 → $50 | $44.78 | +11.66% | 2 | Aug 8, 2024 | |
| BAX Baxter International | Maintains: Neutral | $44 → $42 | $32.63 | +28.72% | 16 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $4.23 | - | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $85 | $90.17 | -5.73% | 12 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $7.98 | +0.25% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $36 → $13 | $13.52 | -3.85% | 5 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $75 | $70.69 | +6.10% | 5 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $100 → $120 | $99.08 | +21.11% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $17 | $9.19 | +84.98% | 3 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $62 | $44.81 | +38.36% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $225 | $266.58 | -15.60% | 3 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $239.20 | +4.52% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $16 | $13.49 | +18.61% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $9.46 | -26.00% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $340 → $181 | $184.77 | -2.04% | 4 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $56 → $43 | $22.93 | +87.53% | 5 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $19.38 | -12.28% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $11.41 | - | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $115.93 | +1.79% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $73.74 | +111.55% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $105 | $84.11 | +24.84% | 11 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $141.44 | -71.72% | 2 | May 5, 2020 |
CeriBell
Nov 5, 2024
Initiates: Overweight
Price Target: $32
Current: $25.06
Upside: +27.69%
Stryker
Oct 30, 2024
Maintains: Overweight
Price Target: $375 → $420
Current: $385.68
Upside: +8.90%
AtriCure
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $36.03
Upside: +11.02%
Edwards Lifesciences
Oct 25, 2024
Maintains: Neutral
Price Target: $72 → $78
Current: $69.54
Upside: +12.17%
DexCom
Oct 25, 2024
Maintains: Neutral
Price Target: $75 → $85
Current: $75.24
Upside: +12.97%
Intuitive Surgical
Oct 11, 2024
Maintains: Overweight
Price Target: $495 → $575
Current: $541.82
Upside: +6.12%
Zimmer Biomet Holdings
Sep 16, 2024
Maintains: Neutral
Price Target: $125 → $120
Current: $109.27
Upside: +9.82%
GE HealthCare Technologies
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $84.90
Upside: +6.01%
Enovis
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $44.78
Upside: +11.66%
Baxter International
Aug 7, 2024
Maintains: Neutral
Price Target: $44 → $42
Current: $32.63
Upside: +28.72%
Aug 7, 2024
Downgrades: Underweight
Price Target: n/a
Current: $4.23
Upside: -
Jul 25, 2024
Maintains: Overweight
Price Target: $82 → $85
Current: $90.17
Upside: -5.73%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $7.98
Upside: +0.25%
May 1, 2024
Downgrades: Neutral
Price Target: $36 → $13
Current: $13.52
Upside: -3.85%
Apr 25, 2024
Maintains: Overweight
Price Target: $115 → $75
Current: $70.69
Upside: +6.10%
Mar 13, 2024
Upgrades: Overweight
Price Target: $100 → $120
Current: $99.08
Upside: +21.11%
Mar 12, 2024
Maintains: Overweight
Price Target: $9 → $17
Current: $9.19
Upside: +84.98%
Feb 29, 2024
Maintains: Overweight
Price Target: $40 → $62
Current: $44.81
Upside: +38.36%
Feb 23, 2024
Maintains: Overweight
Price Target: $190 → $225
Current: $266.58
Upside: -15.60%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $239.20
Upside: +4.52%
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $13.49
Upside: +18.61%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $9.46
Upside: -26.00%
Oct 17, 2023
Maintains: Overweight
Price Target: $340 → $181
Current: $184.77
Upside: -2.04%
May 24, 2023
Downgrades: Underweight
Price Target: $56 → $43
Current: $22.93
Upside: +87.53%
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $19.38
Upside: -12.28%
Nov 9, 2022
Downgrades: Underweight
Price Target: n/a
Current: $11.41
Upside: -
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $115.93
Upside: +1.79%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $73.74
Upside: +111.55%
Dec 17, 2021
Downgrades: Neutral
Price Target: $130 → $105
Current: $84.11
Upside: +24.84%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $141.44
Upside: -71.72%